VivoSeq
Other

Total Body Irradiation

0

Pipeline Programs↗

3

Active Trials↗

0

Companies Involved↗

Total Body Irradiation is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

33/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed3 · 33%
Recruiting3 · 33%
Terminated3 · 33%

Clinical Trials

Trial Activity

9 trials

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Recruiting·PPediatric Transplantation & Cellular Therapy Consortium·Phase 2·NCT03509961·95 enrolled
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT04083183·40 enrolled
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT06110572·18 enrolled
Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation
Completed·—·Phase 1·NCT00903929·19 enrolled
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Completed·VVirginia Commonwealth University·Phase 2·NCT00709592·42 enrolled
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Completed·MMedical College of Wisconsin·Phase 2·NCT03159702·43 enrolled
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Terminated·RRoswell Park Cancer Institute·Phase 2·NCT03333486·31 enrolled
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Terminated·HHackensack Meridian Health·Phase 3·NCT01366612·53 enrolled
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 1·NCT00996359·4 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)